Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update or modification in the study details related to the efficacy and safety evaluation of investigational agents in combination with pembrolizumab for the first-line treatment of extensive-stage small cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:13.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying health conditions and prior treatments required for inclusion in the study. This change provides more comprehensive information about the requirements for participation in the clinical trial.
    Difference
    43%
    Check dated 2024-05-22T21:36:20.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:47:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.